Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Confirmatory study of TA-8317 for cancer breakthrough pain
jRCT2080220301Phase 3
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Oct 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fentanyl in breakthrough cancer pain (BTcP) and cancer (2 arms), sponsored by Mitsubishi Tanabe Pharma Corporation.
02
Drugs
fentanyl
03
Conditions
breakthrough cancer pain (BTcP)cancer
Beyond the preview
Go deeper on jRCT2080220301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220301.